Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.58 |
| ▸ | PPARA | Q07869 | 5/20 | 0.58 |
| ▸ | PPARD | Q03181 | 4/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428177 | 0.90 | PPARA (0.48) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL7320224 | 0.85 | PPARG (0.51) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL7320221 | 0.85 | PPARG (0.51) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL7320228 | 0.85 | PPARG (0.51) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL29052801 | 0.84 | HTR6 (0.58) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL29586750 | 0.83 | CYP4F2 (0.56) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL29587436 | 0.82 | PPARG (0.61) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL29586759 | 0.81 | CYP4F2 (0.56) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL29587734 | 0.81 | CYP4F2 (0.59) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL2133112 | 0.80 | PPARG (0.65) | PPARGPPARAPPARDCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2450346-A1 | Antagonists of the TRPV1 receptor and uses thereof | Abbott Laboratories (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2134678-A2 | N-(5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008079683-A2 | N- (5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | PPARG 1163/4885PPARA 1546/4885PPARD 1099/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | PPARG 1080/4885PPARA 1416/4885PPARD 930/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | PPARG 1163/4885PPARA 1546/4885PPARD 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.